High Intensity Focused Ultrasound denials in California external review
In the California DMHC record, independent physician reviewers decided 42 published external-review cases involving High Intensity Focused Ultrasoundand overturned the plan’s denial in 26.2%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
By condition
| Condition | Decisions | Overturned |
|---|---|---|
| Prostate Cancer | 41 | 24.4% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 26 | 19.2% |
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 16 | 37.5% |
What the reviewers wrote
Where the denial was overturned
Findings: The physician reviewer found thatNature of Statutory Criteria/Case Summary: The patient requested reimbursement for high-intensity focused ultrasound (HIFU).In the review of the available records and the current literature for the treatment of organ-confined prostate cancer, ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance of the prostate is a recommended therapy for the treatment of this patient's prostate cancer. The American Urological Association (AUA) guidelines state that ablation may be considered in select, appropriately informed patients. The authors indicated that patients being considered for ablation should have intermediate-risk prostate cancer.
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for high-intensity focused ultrasound (HIFU) services. The American Urological Association (AUA) guidelines on clinically localized prostate cancers note that ablation may be considered in select, appropriately informed patients and that patients being considered for ablation should have intermediate-risk prostate cancer. Based on these guidelines and other studies, high-intensity focused ultrasound is now a standard treatment option for certain types of prostate cancer and can help patients avoid the complications of prostatectomy. In this case, the patient has been diagnosed with Gleason 3+4=7 prostate cancer based on a prostate biopsy obtained due to an elevated PSA. The record reveals that the patient had a UCSF-CAPRA consistent with intermediate-risk disease.
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for high-intensity focused ultrasound (HIFU). Findings: The physician reviewer found that HIFU is considered a minimally invasive treatment option for localized prostate cancer that uses focused ultrasound energy to locally heat and destroy diseased tissue through ablation. HIFU is often utilized in patients who are unable to tolerate surgery or radiation treatment. Other conventional treatment options for the management of patients with early-stage localized prostate cancer include radical prostatectomy, cryotherapy, external beam radiation treatment, and brachytherapy radiation treatment. There are several studies that have demonstrated good functional outcomes and a well-tolerated side effect profile following HIFU treatment in the setting of localized prostate cancer.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for high-intensity focused ultrasound (HIFU). HIFU consists of focused ultrasound waves emitted from a transducer that cause tissue damage by mechanical and thermal effects as well as by cavitation. HIFU has been increasingly used for the treatment of patients with localized prostate cancer. Potential candidates are patients with low-to-moderate risk prostate cancer. The available literature primarily consists of prospective case series and retrospective studies showing short- to intermediate-term outcomes for patients with localized prostate cancer. However, there is a paucity of prospective randomized controlled trials with long-term follow-up available for analysis.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving High Intensity Focused Ultrasound, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY